Stocks

Magazine articles on individual stocks, valuation, accounting standards, IPO's, brokerages, exchanges.

Old Articles: <Older 28421-28430 Newer>

The Motley Fool February 1, 2008 Matt Koppenheffer	Irwin Soars! Irwin Financial jumped 28% on a fourth-quarter earnings report that showed signs of life.
The Motley Fool February 1, 2008 David Lee Smith	Baker Hughes' Expensive Pair of Pennies It didn't quite meet analysts' expectations, but oilfield services company Baker Hughes still merits attention.
The Motley Fool January 31, 2008 Mac Greer	Fool Video: Chipotle, Starbucks, and the Next McDonald's? Is Buffalo Wild Wings the next McDonald's? Is Chipotle? Will Starbucks perk up after disappointing earnings? These questions and others are discussed in this video.
The Motley Fool January 31, 2008 David Lee Smith	UPS' Solid Delivery UPS took a $6.1 billion charge for the December-ended quarter as part of its new contract with the Teamsters' union. As a result of that one-time item, its per-share earnings amounted to a loss of $2.46 per share, compared to earnings of $1.04 a year ago. Read on to see why this is a good thing.
The Motley Fool January 31, 2008 Anders Bylund	EA Takes Fantasy Warfare to Taiwan Game addicts meet a potentially addictive new game, Warhammer Online: Age of Reckoning. Will profits ensue?
The Motley Fool January 31, 2008 Rich Smith	Netflix's Hundred-Mil Buyback Netflix plans to buy $100 million of its own stock over the course of this year.
The Motley Fool January 31, 2008 Brian Lawler	When Nutraceuticals Attack After a failed phase 3 trial, Neurochem plans to market Alzhemed as a nutraceutical supplement.
The Motley Fool January 31, 2008 Toby Shute	Balk to the Future High energy costs are eating away at coal miner Peabody Energy's operating efficiency.
The Motley Fool January 31, 2008 Dave Mock	Investors Yawn at Vodafone's Brawn The world's largest wireless service provider by revenue grew the top line by 16%, thanks to recent acquisitions, but respectable results fail to stir the market.
The Motley Fool January 31, 2008 Brian Lawler	Prioritizing Millennium The FDA grants a speedy review for Millennium Pharmaceuticals's lead multiple myeloma drug.
<Older 28421-28430 Newer> Return to current articles.